
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1689889/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002–2033: the ITA.LI.CA database. Gut, 2023, 72, 141-152.	12.1	57
2	Is there an â€~ideal' diet for patients with NAFLD?. European Journal of Clinical Investigation, 2022, 52, e13659.	3.4	28
3	Surveillance for hepatocellular carcinoma with a 3-months interval in "extremely high-risk―patients does not further improve survival. Digestive and Liver Disease, 2022, 54, 927-936.	0.9	4
4	Treatment allocation in patients with hepatocellular carcinoma: Need for a paradigm shift?. Liver Cancer International, 2022, 3, 34-36.	1.3	7
5	Transarterial Chemoembolization for Hepatocellular Carcinoma in Clinical Practice: Temporal Trends and Survival Outcomes of an Iterative Treatment. Frontiers in Oncology, 2022, 12, 822507.	2.8	5
6	Pharmacotherapies in eosinophilic esophagitis: state of the art. Minerva Gastroenterology, 2022, 68, 69-76.	0.5	0
7	EASL Clinical Practice Guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis. Journal of Hepatology, 2022, 76, 1151-1184.	3.7	112
8	Diabetes medications and risk of HCC. Hepatology, 2022, 76, 1880-1897.	7.3	39
9	Primary biliary cholangitis: perception and expectation of illness. Digestive and Liver Disease, 2022, 54, 1230-1233.	0.9	1
10	Characteristics and survival of patients with primary biliary cholangitis and hepatocellular carcinoma. Digestive and Liver Disease, 2022, 54, 1215-1221.	0.9	3
11	Response to COVID-19 Vaccination in Patients with Inflammatory Bowel Disease on Biological Treatment. Gastrointestinal Disorders, 2022, 4, 77-83.	0.8	0
12	The international normalized ratio – Great for prediction of bleeding in patients taking vitamin K antagonists, useless for prediction of bleeding in patients with chronic liver disease. Journal of Thrombosis and Haemostasis, 2022, 20, 1565-1567.	3.8	0
13	Achalasia and Obstructive Motor Disorders Are Not Uncommon in Patients With Eosinophilic Esophagitis. Clinical Gastroenterology and Hepatology, 2021, 19, 1554-1563.	4.4	34
14	Monofocal hepatocellular carcinoma: How much does size matter?. Liver International, 2021, 41, 396-407.	3.9	10
15	Applicability of Parameters for the Noninvasive Diagnosis of Esophageal Varices Needing Treatment to Hepatitis C Virus–Cured Patients. Clinical Infectious Diseases, 2021, 72, 1862-1863.	5.8	1
16	COVIDâ€19 and liver disease: Not all evil comes to harm. Liver International, 2021, 41, 237-238.	3.9	11
17	The changing scenario of hepatocellular carcinoma in Italy: an update. Liver International, 2021, 41, 585-597.	3.9	69
18	Improving prognosis of patients with very early hepatocellular carcinoma: How far are we going?. Digestive and Liver Disease, 2021, 53, 143-145.	0.9	1

#	Article	IF	CITATIONS
19	Effects of SARS-CoV-2 emergency measures on high-risk lesions detection: a multicentre cross-sectional study. Gut, 2021, 70, 1241-1243.	12.1	8
20	Time-Varying mHAP-III Is the Most Accurate Predictor of Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. Liver Cancer, 2021, 10, 126-136.	7.7	6
21	Identification of Clinical Phenotypes and Related Survival in Patients with Large HCCs. Cancers, 2021, 13, 592.	3.7	5
22	Surveillance as Determinant of Long-Term Survival in Non-Transplanted Hepatocellular Carcinoma Patients. Cancers, 2021, 13, 897.	3.7	9
23	Proactive Measures Aimed at Improving Appropriateness of Use of Proton Pump Inhibitors in Clinical Practice. Clinical Gastroenterology and Hepatology, 2021, 19, 410.	4.4	Ο
24	Procedureâ€related bleeding risk in patients with cirrhosis and severe thrombocytopenia. European Journal of Clinical Investigation, 2021, 51, e13508.	3.4	20
25	Bleeding events in lusutrombopagâ€treated thrombocytopenic patients. European Journal of Clinical Investigation, 2021, 51, e13503.	3.4	7
26	Changes in hepatocellular carcinoma aggressiveness characteristics with an increase in tumor diameter. International Journal of Biological Markers, 2021, 36, 54-61.	1.8	8
27	Liver Resection for Patients with Intermediate Stage Hepatocellular Carcinoma: Beyond Rigid Staging Systems Towards a More Personalized Therapeutic Approach. Journal of Gastrointestinal Surgery, 2021, 25, 1078-1079.	1.7	1
28	Pattern of macrovascular invasion in hepatocellular carcinoma. European Journal of Clinical Investigation, 2021, 51, e13542.	3.4	18
29	Overview of Prognostic Systems for Hepatocellular Carcinoma and ITA.LI.CA External Validation of MESH and CNLC Classifications. Cancers, 2021, 13, 1673.	3.7	21
30	A Nomogram-Based Prognostic Model for Advanced Hepatocellular Carcinoma Patients Treated with Sorafenib: A Multicenter Study. Cancers, 2021, 13, 2677.	3.7	6
31	Prevention Strategies for Esophageal Cancer—An Expert Review. Cancers, 2021, 13, 2183.	3.7	19
32	Sleeve gastrectomy may double the risk of esophageal adenocarcinoma in morbidly obese patients. Surgery for Obesity and Related Diseases, 2021, 17, 1029-1030.	1.2	3
33	Immunoglobulin, nucleos(t)ide analogues and hepatitis B virus recurrence after liver transplant: A metaâ€analysis. European Journal of Clinical Investigation, 2021, 51, e13575.	3.4	11
34	Refractoriness to Treatment Suggests That Clinical Evaluation Should Go Beyond the Diagnosis of Reflux Disease. Clinical Gastroenterology and Hepatology, 2021, 19, 1077-1078.	4.4	0
35	Dietary Management of Eosinophilic Esophagitis: Tailoring the Approach. Nutrients, 2021, 13, 1630.	4.1	21
36	Elevated Adherence to Vaccination Against SARS-CoV-2 Among Patients with Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2021, 15, 2142-2143.	1.3	7

#	Article	IF	CITATIONS
37	Letter: predictive factors for treatment discontinuation in IBD—antiâ€TNF trough levels and antiâ€drug antibodies. Alimentary Pharmacology and Therapeutics, 2021, 54, 536-537.	3.7	1
38	Recalibrating survival prediction among patients receiving transâ€arterial chemoembolization for hepatocellular carcinoma. Liver Cancer International, 2021, 2, 45-53.	1.3	2
39	Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors and Applicability of First-Line Atezolizumab/Bevacizumab in a Real-Life Setting. Journal of Clinical Medicine, 2021, 10, 3201.	2.4	13
40	Therapeutic drug monitoring in Crohn's disease patients treated with anti-TNF. European Journal of Gastroenterology and Hepatology, 2021, Publish Ahead of Print, .	1.6	3
41	High acceptance rate of COVID-19 vaccination in liver transplant recipients. Journal of Hepatology, 2021, 75, 483-484.	3.7	8
42	Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study Digestive and Liver Disease, 2021, 53, 1011-1019.	0.9	7
43	Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy , 2021, 9, e003311.		66
44	The ITA.LI.CA Consortium: how multicentre collaboration helped shape the management of patients with hepatocellular carcinoma on the basis of real-world evidence Annals of Hepatology, 2021, , 100564.	1.5	1
45	Material deprivation affects the management and clinical outcome of hepatocellular carcinoma in a high-resource environment. European Journal of Cancer, 2021, 158, 133-143.	2.8	4
46	Eosinophilic esophagitis: novel concepts regarding pathogenesis and clinical manifestations. Minerva Gastroenterology, 2021, , .	0.5	5
47	Obeticholic Acid Improves Aminotransferases Early during Treatment in Patients with Primary Biliary Cholangitis Not Responding to Ursodeoxycholic Acid: A Study in Clinical Practice. Immuno, 2021, 1, 457-467.	1.5	0
48	Letter: vedolizumab or a second antiâ€TNF—no difference in efficacy for primary biologic failures with IBD. Alimentary Pharmacology and Therapeutics, 2021, 53, 1044-1045.	3.7	1
49	Aminopyrine breath test predicts liverâ€related events and death in HCVâ€related cirrhosis on SVR after DAA therapy. Liver International, 2020, 40, 530-538.	3.9	1
50	Outcomes of Liver Transplant for Adults With Wilson's Disease. Liver Transplantation, 2020, 26, 507-516.	2.4	12
51	Eradication of hepatitis C virus infection disclosing a previously hidden, underlying autoimmune hepatitis and HCV. Annals of Hepatology, 2020, 19, 222-225.	1.5	5
52	P465 Therapeutic drug monitoring in Crohn's disease patients, a comparison between homogeneous mobility shift assay and point of care method. Journal of Crohn's and Colitis, 2020, 14, S412-S412.	1.3	0
53	Esophageal reflux hypersensitivity: Non-GERD or still GERD?. Digestive and Liver Disease, 2020, 52, 1413-1420.	0.9	16
54	Nuts and Non-Alcoholic Fatty Liver Disease: Are Nuts Safe for Patients with Fatty Liver Disease?. Nutrients, 2020, 12, 3363.	4.1	16

#	Article	IF	CITATIONS
55	Surveillance for Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease: Universal or Selective?. Cancers, 2020, 12, 1422.	3.7	41
56	Appropriateness of proton pump inhibitors treatment in clinical practice: Prospective evaluation in outpatients and perspective assessment of drug optimisation. Digestive and Liver Disease, 2020, 52, 862-868.	0.9	11
57	International and multicenter realâ€world study of sorafenibâ€ŧreated patients with hepatocellular carcinoma under dialysis. Liver International, 2020, 40, 1467-1476.	3.9	15
58	Risk factors for bleeding following oesophageal band ligation: Providing further evidence to ameliorate clinical practice. Digestive and Liver Disease, 2020, 52, 792-793.	0.9	0
59	Hepatitis C virus therapy in children: No one should be left behind. Liver International, 2020, 40, 283-285.	3.9	1
60	<p>Vonoprazan Fumarate for the Treatment of Gastric Ulcers: A Short Review on Emerging Data</p> . Clinical and Experimental Gastroenterology, 2020, Volume 13, 99-104.	2.3	14
61	Undefined/non-malignant hepatic nodules are associated with early occurrence of HCC in DAA-treated patients with HCV-related cirrhosis. Journal of Hepatology, 2020, 73, 593-602.	3.7	38
62	Soluble CD163 and mannose receptor as markers of liver disease severity and prognosis in patients with primary biliary cholangitis. Liver International, 2020, 40, 1408-1414.	3.9	22
63	Course of oesophageal varices and performance of noninvasive predictors following Hepatitis C Virus clearance in compensated advanced chronic liver disease. European Journal of Clinical Investigation, 2020, 50, e13231.	3.4	8
64	Concerns related to COVIDâ€19 pandemic among patients with inflammatory bowel disease and its influence on patient management. European Journal of Clinical Investigation, 2020, 50, e13233.	3.4	15
65	Comparison of Two Different Techniques to Assess Adalimumab Trough Levels in Patients with Crohn's Disease. Journal of Gastrointestinal and Liver Diseases, 2020, 24, 451-456.	0.9	21
66	A Closer Look at Factors Associated With Bleeding in Cirrhotic Patients. American Journal of Gastroenterology, 2019, 114, 364-365.	0.4	1
67	A randomized, 6-wk trial of a low FODMAP diet in patients with inflammatory bowel disease. Nutrition, 2019, 67-68, 110542.	2.4	42
68	Platelets and Hepatocellular Cancer: Bridging the Bench to the Clinics. Cancers, 2019, 11, 1568.	3.7	27
69	Overview of Immune Checkpoint Inhibitors Therapy for Hepatocellular Carcinoma, and The ITA.LI.CA Cohort Derived Estimate of Amenability Rate to Immune Checkpoint Inhibitors in Clinical Practice. Cancers, 2019, 11, 1689.	3.7	44
70	Ramucirumab as a second-line treatment for hepatocellular carcinoma: reaching out further to patients with elevated alpha-fetoprotein. Hepatobiliary Surgery and Nutrition, 2019, 8, 515-518.	1.5	1
71	High anti-TNF alfa drugs trough levels are not associated with the occurrence of adverse events in patients with inflammatory bowel disease. Scandinavian Journal of Gastroenterology, 2019, 54, 1220-1225.	1.5	6
72	PS-119-Time-varying mHAP III is the most accurate score in predicting survival in patients wit hepatocellular carcinoma undergoing trans-arterial chemoembolization. Journal of Hepatology, 2019, 70, e75.	3.7	0

#	Article	IF	CITATIONS
73	The concept of therapeutic hierarchy for patients with hepatocellular carcinoma: A multicenter cohort study. Liver International, 2019, 39, 1478-1489.	3.9	41
74	SAT-038-Lusutrombopag for treatment of thrombocytopenia in patients with chronic liver disease who are undergoing planned invasive procedures: pooled safety analysis of bleeding-related adverse events. Journal of Hepatology, 2019, 70, e643.	3.7	1
75	Long term results of down-staging and liver transplantation for patients with hepatocellular carcinoma beyond the conventional criteria. Scientific Reports, 2019, 9, 3781.	3.3	18
76	Influence of HIV Infection on the Natural History of Hepatocellular Carcinoma: Results From a Global Multicohort Study. Journal of Clinical Oncology, 2019, 37, 296-304.	1.6	36
77	Micro-elimination of hepatitis C virus infection in β-Thalassaemia major patients: Positively moving towards the World Health Organisation 2030 eradication goal. Digestive and Liver Disease, 2019, 51, 568-569.	0.9	2

Acquired Hepatocerebral Degeneration in the Absence of Portosystemic Shunting. Journal of Clinical

#	Article	IF	CITATIONS
91	Long-Term Follow-Up Study of Liver-Related Outcome After Bilio-Pancreatic Diversion in Patients with Initial, Significant Liver Damage. Digestive Diseases and Sciences, 2018, 63, 1946-1951.	2.3	2
92	Utility of Tumor Burden Score to Stratify Prognosis of Patients with Hepatocellular Cancer: Results of 4759 Cases from ITA.LI.CA Study Group. Journal of Gastrointestinal Surgery, 2018, 22, 859-871.	1.7	38
93	Infliximab trough levels and persistent vs transient antibodies measured early after induction predict long-term clinical remission in patients with inflammatory bowel disease. Digestive and Liver Disease, 2018, 50, 452-456.	0.9	22
94	Editorial: a step forward in refining prognostication for patients with HIVâ€associated hepatocellular carcinoma. Alimentary Pharmacology and Therapeutics, 2018, 47, 133-134.	3.7	1
95	Patients with advanced hepatocellular carcinoma need a personalized management: A lesson from clinical practice. Hepatology, 2018, 67, 1784-1796.	7.3	93
96	Low Fibrinogen Levels Are Associated with Bleeding After Varices Ligation in Thrombocytopenic Cirrhotic Patients. Annals of Hepatology, 2018, 17, 830-835.	1.5	25
97	Improvement in Waldenström's Macroglobulinemia after Successful Treatment of HCV with Direct-acting Antivirals. Annals of Hepatology, 2018, 17, 1072-1077.	1.5	3
98	Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN). Internal and Emergency Medicine, 2018, 13, 1139-1166.	2.0	2
99	Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN), Journal of Nephrology, 2018, 31, 685-712.	2.0	3
100	Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN). Digestive and Liver Disease, 2018, 50, 1133-1152.	0.9	5
101	Bleeding after paracentesis in patients with decompensated cirrhosis and acute kidney injury: The perfect storm. Liver International, 2018, 38, 2101-2101.	3.9	1
102	Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65Âyears with HCV genotype 1 cirrhosis. Infection, 2018, 46, 607-615.	4.7	7
103	Letter: it is time to adopt new objective parameters to accurately identify patients with functional heartburn. Alimentary Pharmacology and Therapeutics, 2018, 48, 107-108.	3.7	2
104	Restaging Patients With Hepatocellular Carcinoma Before Additional Treatment Decisions: A Multicenter Cohort Study. Hepatology, 2018, 68, 1232-1244.	7.3	26
105	NASH-related and cryptogenic cirrhosis similarities extend beyond cirrhosis. Journal of Hepatology, 2018, 69, 972-973.	3.7	4
106	Reduction in <scp>TIMP</scp> â€2 serum levels predicts remission of inflammatory bowel diseases. European Journal of Clinical Investigation, 2018, 48, e13002.	3.4	13
107	Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score. The Lancet Gastroenterology and Hepatology, 2018, 3, 626-634.	8.1	103
108	Metabolic disorders across hepatocellular carcinoma in Italy. Liver International, 2018, 38, 2028-2039.	3.9	10

#	Article	IF	CITATIONS
109	Recurrence of hepatocellular carcinoma after direct acting antiviral treatment for hepatitis C virus infection: Literature review and risk analysis. Digestive and Liver Disease, 2018, 50, 1105-1114.	0.9	41
110	Plasma cholesterol and lipoprotein levels in relation to tumor aggressiveness and survival in HCC patients. International Journal of Biological Markers, 2018, 33, 423-431.	1.8	23
111	Laser ablation is superior to TACE in large-sized hepatocellular carcinoma: a pilot case-control study. Oncotarget, 2018, 9, 17483-17490.	1.8	12
112	Improvement in Waldenström's Macroglobulinemia after Successful Treatment of HCV with Direct-acting Antivirals. Annals of Hepatology, 2018, 17, 0-10.	1.5	0
113	Liver Stiffness Improvement Is Associated With Amelioration of Indirect Parameters of Portal Hypertension One Year After Sustained Virological Response to Direct Acting Antivirals in Chronic Hepatitis C Patients. American Journal of Gastroenterology, 2018, 113, S577.	0.4	0
114	A metaâ€analysis of single <scp>HCV</scp> â€untreated arm of studies evaluating outcomes after curative treatments of <scp>HCV</scp> â€related hepatocellular carcinoma. Liver International, 2017, 37, 1157-1166.	3.9	70
115	Noninvasive assessment of varices needing treatment in patients with advanced chronic liver disease: No one should be left behind. Hepatology, 2017, 65, 2131-2131.	7.3	1
116	Common issues in the management of patients in the waiting list and after liver transplantation. Digestive and Liver Disease, 2017, 49, 241-253.	0.9	23
117	Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma. Journal of Hepatology, 2017, 67, 65-71.	3.7	83
118	Adalimumab Therapy Rather than Azathioprine and Mesalamine is Able to Halt Crohn's Disease Progression after Resective Surgery and a Post-Hoc Analysis of a Prospective Randomized Study. Gastroenterology, 2017, 152, S774.	1.3	3
119	Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. The Lancet Gastroenterology and Hepatology, 2017, 2, 427-434.	8.1	15
120	A Nodule, is a Nodule, is a Nodule: May Alpha-Fetoprotein Make the Difference?. American Journal of Gastroenterology, 2017, 112, 1340.	0.4	1
121	Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of <scp>HCV</scp> eradication does not depend on the use of interferon. Alimentary Pharmacology and Therapeutics, 2017, 45, 160-168.	3.7	70
122	Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma. Liver International, 2017, 37, 423-433.	3.9	46
123	Personalized treatment of patients with very early hepatocellular carcinoma. Journal of Hepatology, 2017, 66, 412-423.	3.7	119
124	The evolutionary scenario of hepatocellular carcinoma in Italy: an update. Liver International, 2017, 37, 259-270.	3.9	67
125	Anti-TNF therapy is able to stabilize bowel damage progression in patients with Crohn's disease. A study performed using the Lémann Index. Digestive and Liver Disease, 2017, 49, 175-180.	0.9	25
126	Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network. PLoS ONE, 2017, 12, e0185728.	2.5	37

#	Article	IF	CITATIONS
127	A Liver Index and its Relationship to Indices of HCC Aggressiveness. Journal of Integrative Oncology, 2016, 5, .	0.3	28
128	Comparison between alcohol―and hepatitis C virusâ€related hepatocellular carcinoma: clinical presentation, treatment and outcome. Alimentary Pharmacology and Therapeutics, 2016, 43, 385-399.	3.7	59
129	Years of life that could be saved from prevention of hepatocellular carcinoma. Alimentary Pharmacology and Therapeutics, 2016, 43, 814-824.	3.7	20
130	Adalimumab trough serum levels and anti-adalimumab antibodies in the long-term clinical outcome of patients with Crohn's disease. Scandinavian Journal of Gastroenterology, 2016, 51, 1081-1086.	1.5	36
131	Sa1933 Biological Therapy Is Able to Halt Crohn's Disease Progression: A Prospective, Long Term Study Using the LéMann Index. Gastroenterology, 2016, 150, S408.	1.3	0
132	Tu2009 Does Lémann Index Reflect the Quality of Life in Crohn Disease Patients on Treatment With Biological Therapy?. Gastroenterology, 2016, 150, S1004-S1005.	1.3	1
133	Portal vein thrombosis and chronic liver disease progression: The closer you look the more you see. Hepatology, 2016, 63, 342-343.	7.3	6
134	Hepatobiliary and Pancreatic: A rare cause of portal hypertension. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 11-11.	2.8	2
135	Letter: faecal volatile organic metabolites, promising biomarkers in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2016, 43, 1240-1241.	3.7	3
136	Health-related quality of life in thrombocytopenic patients with chronic hepatitis C with or without cirrhosis in the ENABLE-1 and ENABLE-2 studies. Health and Quality of Life Outcomes, 2016, 14, 49.	2.4	2
137	Positive PET in a Patient With Esophageal Leiomyoma. American Journal of Gastroenterology, 2016, 111, 767.	0.4	4
138	Hemostatic balance in patients with liver cirrhosis: Report of a consensus conference. Digestive and Liver Disease, 2016, 48, 455-467.	0.9	57
139	Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma – The SHELTER study. Journal of Hepatology, 2016, 65, 280-288.	3.7	98
140	Application of the Intermediate-Stage Subclassification to Patients With Untreated Hepatocellular Carcinoma. American Journal of Gastroenterology, 2016, 111, 70-77.	0.4	59
141	Prognostic role of mean platelet volume in patients with cirrhosis. Digestive and Liver Disease, 2016, 48, 409-413.	0.9	16
142	An independent validation of the mortality score for the short-term prognostic prediction in patients with chronic HCV infection and advanced liver disease. Gut, 2016, 65, 183-184.	12.1	0
143	Development and Validation of a New Prognostic System for Patients with Hepatocellular Carcinoma. PLoS Medicine, 2016, 13, e1002006.	8.4	113
144	Breath Tests to Assess Alcoholic Liver Disease. Reviews on Recent Clinical Trials, 2016, 11, 185-190.	0.8	2

#	Article	IF	CITATIONS
145	Screening for Hepatocellular Carcinoma in Chronic Liver Disease. Annals of Internal Medicine, 2015, 162, 239.	3.9	2
146	Utilityâ€based criteria for selecting patients with hepatocellular carcinoma for liver transplantation: A multicenter cohort study using the alphaâ€fetoprotein model as a survival predictor. Liver Transplantation, 2015, 21, 1250-1258.	2.4	10
147	Optimal management of constipation associated with irritable bowel syndrome. Therapeutics and Clinical Risk Management, 2015, 11, 691.	2.0	11
148	Hepatocellular Carcinoma Is the Most Frequent Final Diagnosis of Focal Liver Lesions Identified in a Cross-Sectional Evaluation of Patients with Chronic Liver Disease in Saudi Arabia. Journal of Cancer Research, 2015, 2015, 1-4.	0.7	1
149	Correlation between LDH levels and response to sorafenib in HCC patients: an analysis of the ITA.LI.CA database. International Journal of Biological Markers, 2015, 30, 65-72.	1.8	8
150	Economic assessment of eltrombopag in the treatment of thrombocytopenia. Expert Review of Pharmacoeconomics and Outcomes Research, 2015, 15, 713-720.	1.4	4
151	Prognosis of untreated hepatocellular carcinoma. Hepatology, 2015, 61, 184-190.	7.3	188
152	BCLC stage B hepatocellular carcinoma and transcatheter arterial chemoembolization: a 20â€year survey by the Italian Liver Cancer group. Liver International, 2015, 35, 223-231.	3.9	41
153	Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: A multicentre study. Journal of Hepatology, 2015, 62, 617-624.	3.7	184
154	A new approach to the use of α-fetoprotein as surveillance test for hepatocellular carcinoma in patients with cirrhosis. British Journal of Cancer, 2015, 112, 69-76.	6.4	66
155	12 weeks of interferon-based therapy is feasible in patients with hepatitis C-related cirrhosis and thrombocytopenia: A post hoc analysis of eltrombopag studies. Digestive and Liver Disease, 2015, 47, 864-868.	0.9	0
156	Adalimumab Trough Levels and Response to Biological Treatment in Patients With Inflammatory Bowel Disease: A Useful Cutoff in Clinical Practice. American Journal of Gastroenterology, 2015, 110, 472-473.	0.4	6
157	Therapeutic Management of Chronic Hepatitis B in Clinical Practice. Journal of Clinical Gastroenterology, 2015, 49, 228-234.	2.2	4
158	Nonâ€cirrhotic thrombocytopenic patients with hepatitis <scp>C</scp> virus: Characteristics and outcome of antiviral therapy. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 1301-1308.	2.8	5
159	Platelet Dysfunction: Status of Thrombopoietin in Thrombocytopenia Associated with Chronic Liver Failure. Seminars in Thrombosis and Hemostasis, 2015, 41, 455-461.	2.7	14
160	Undetectable <scp>HCV</scp> â€ <scp>RNA</scp> at treatmentâ€week 8 results in highâ€sustained virological response in <scp>HCV</scp> G1 treatmentâ€experienced patients with advanced liver disease: the International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program. Journal of Viral Hepatitis, 2015, 22, 469-480.	2.0	9
161	Starry Liver: An Unexpected Diagnosis. ACG Case Reports Journal, 2015, 2, 77-78.	0.4	3
162	Use of Liver Breath Tests to Assess Severity of Nonalcoholic Fatty Liver Disease. Reviews on Recent Clinical Trials, 2015, 9, 178-184.	0.8	2

#	Article	IF	CITATIONS
163	Epidemiological and Clinical Features of Hepatitis Delta in HBsAg-Positive Patients by HIV Status. Antiviral Therapy, 2015, 20, 193-197.	1.0	6
164	Significance of Platelet and AFP Levels and Liver Function Parameters for HCC Size and Survival. International Journal of Biological Markers, 2014, 29, 215-223.	1.8	36
165	Eltrombopag in patients with chronic hepatitis C and thrombocytopenia. Future Virology, 2014, 9, 9-20.	1.8	0
166	Correction of hemostatic abnormalities and portal pressure variations in patients with cirrhosis. Hepatology, 2014, 60, 1442-1442.	7.3	37
167	Improving survival of cirrhosis patients with hepatocellular carcinoma through application of standard of care. Hepatology, 2014, 60, 1446-1447.	7.3	5
168	Prognostic Prediction and Identification of Candidates for Salvage Liver Transplantation Among Patients With Early Hepatocellular Carcinoma. Liver Transplantation, 2014, 20, 1150-1151.	2.4	2
169	Estimation of lead-time bias and its impact on the outcome of surveillance for the early diagnosis of hepatocellular carcinoma. Journal of Hepatology, 2014, 61, 333-341.	3.7	110
170	Factors That Affect Efficacy of Ultrasound Surveillance for Early Stage Hepatocellular Carcinoma in Patients With Cirrhosis. Clinical Gastroenterology and Hepatology, 2014, 12, 1927-1933.e2.	4.4	108
171	Platelet count and survival of patients with compensated cirrhosis and small hepatocellular carcinoma treated with surgery. Hepatology, 2014, 59, 1649-1649.	7.3	5
172	Determinants of alphaâ€fetoprotein levels in patients with hepatocellular carcinoma: Implications for its clinical use. Cancer, 2014, 120, 2150-2157.	4.1	56
173	Pegylated interferon α plus ribavirin for the treatment of chronic hepatitis C: A multicentre independent study supported by the Italian Drug Agency. Digestive and Liver Disease, 2014, 46, 826-832.	0.9	12
174	Accuracy of α-Fetoprotein Measurement in Detection of Hepatocellular Carcinoma—1 More Nail in the Coffin. Clinical Gastroenterology and Hepatology, 2014, 12, 2138-2139.	4.4	2
175	Association of Abnormal Plasma Bilirubin With Aggressive Hepatocellular Carcinoma Phenotype. Seminars in Oncology, 2014, 41, 252-258.	2.2	40
176	Identification of Two Clinical Hepatocellular Carcinoma Patient Phenotypes From Results of Standard Screening Parameters. Seminars in Oncology, 2014, 41, 406-414.	2.2	14
177	Eltrombopag Increases Platelet Numbers in Thrombocytopenic Patients With HCV Infection and Cirrhosis, Allowing for Effective Antiviral Therapy. Gastroenterology, 2014, 146, 442-452.e1.	1.3	123
178	Low Alpha-Fetoprotein HCC and the Role of GGTP. International Journal of Biological Markers, 2014, 29, 395-402.	1.8	21
179	Platelet count manipulation and modification of global haemostasis tests in patients with chronic liver disease: almost there, almost there…. Liver International, 2013, 33, 325-326.	3.9	6
180	Hepatocellular carcinoma in patients without cirrhosis in Italy. Digestive and Liver Disease, 2013, 45, 164-169.	0.9	38

#	Article	IF	CITATIONS
181	Position paper of the Italian Association for the Study of the Liver (AISF): The multidisciplinary clinical approach to hepatocellular carcinoma. Digestive and Liver Disease, 2013, 45, 712-723.	0.9	155
182	Which Anticoagulant Drug Should Be Used to Treat Portal Vein Thrombosis in Patients With Chronic Liver Disease?. Clinical Gastroenterology and Hepatology, 2013, 11, 103.	4.4	3
183	Eltrombopag in patients with chronic liver disease. Expert Opinion on Pharmacotherapy, 2013, 14, 669-678.	1.8	13
184	Thrombocytopenia in Patients with Chronic Liver Disease: What's in a Name?. Digestive Diseases and Sciences, 2013, 58, 299-301.	2.3	10
185	Relationship Between 13C-Aminopyrine Breath Test and the MELD Score and Its Long-Term Prognostic Use in Patients with Cirrhosis. Digestive Diseases and Sciences, 2013, 58, 3024-3028.	2.3	7
186	Feasibility of the Cutâ€andâ€Push Method for Removing Largeâ€Caliber Soft Percutaneous Endoscopic Gastrostomy Devices. Nutrition in Clinical Practice, 2013, 28, 490-492.	2.4	17
187	Surveillance for early diagnosis of hepatocellular carcinoma: How best to do it?. World Journal of Gastroenterology, 2013, 19, 8808.	3.3	72
188	Rise and fall of <scp>HCV</scp> â€related hepatocellular carcinoma in Italy: a longâ€term survey from the <scp>ITA</scp> . <scp>LI</scp> . <scp>CA</scp> centres. Liver International, 2013, 33, 1420-1427.	3.9	13
189	Influence of clinically significant portal hypertension on survival after hepatic resection for hepatocellular carcinoma in cirrhotic patients. Liver International, 2013, 33, 1594-1600.	3.9	46
190	Surveillance for Hepatocellular Carcinoma: Just Do It!. American Journal of Gastroenterology, 2013, 108, 1013-1014.	0.4	5
191	Adequate Interval For Hepatocellular Carcinoma Surveillance. American Journal of Gastroenterology, 2013, 108, 1174.	0.4	1
192	Predicting the posttransplant prognosis of patients with hepatocellular carcinoma: What lies beneath alpha-fetoprotein?. Liver Transplantation, 2013, 19, 1166-1167.	2.4	1
193	Resminostat in advanced hepatocellular carcinoma (HCC): Overall survival subgroup analysis of prognostic factors in the SHELTER trial Journal of Clinical Oncology, 2013, 31, e15088-e15088.	1.6	5
194	Therapeutic Management of Chronic Hepatitis B in Clinical Practice: A Study in 505 Patients. American Journal of Gastroenterology, 2013, 108, S110.	0.4	0
195	Peg-interfon alpha-2a and low-dose ribavirin for treatment of hepatitis C virus infection in patients with sickle-cell anemia in Saudi Arabia. Annals of Saudi Medicine, 2013, 33, 610-613.	1.1	1
196	Ten-Year Outcome of Radiofrequency Thermal Ablation for Hepatocellular Carcinoma: An Italian Experience. American Journal of Gastroenterology, 2012, 107, 1588-1589.	0.4	6
197	Effectiveness of α-fetoprotein for hepatocellular carcinoma surveillance: the return of the living-dead?. Expert Review of Gastroenterology and Hepatology, 2012, 6, 441-444.	3.0	13
198	Liver transplantation for hepatocellular carcinoma in clinical practice. European Journal of Gastroenterology and Hepatology, 2012, 24, 195-202.	1.6	15

#	Article	IF	CITATIONS
199	Safety of Cardiac Surgery in Cirrhotic Patients: Going to the Heart of the Matter. Clinical Gastroenterology and Hepatology, 2012, 10, 450-451.	4.4	1
200	Peripheral blood cytopaenia limiting initiation of treatment in chronic hepatitis C patients otherwise eligible for antiviral therapy. Liver International, 2012, 32, 1113-1119.	3.9	27
201	The changing scenario of hepatocellular carcinoma over the last two decades in Italy. Journal of Hepatology, 2012, 56, 397-405.	3.7	84
202	Cost-effectiveness of semi-annual surveillance for hepatocellular carcinoma in cirrhotic patients of the Italian Liver Cancer population. Journal of Hepatology, 2012, 56, 1089-1096.	3.7	61
203	TACE treatment in hepatocellular carcinoma: What should we do now?. Journal of Hepatology, 2012, 57, 221-222.	3.7	21
204	Alpha-fetoprotein has no prognostic role in small hepatocellular carcinoma identified during surveillance in compensated cirrhosis. Hepatology, 2012, 56, 1371-1379.	7.3	130
205	Eltrombopag before Procedures in Patients with Cirrhosis and Thrombocytopenia. New England Journal of Medicine, 2012, 367, 716-724.	27.0	274
206	Comment to "Platelet count/spleen diameter ratio for non-invasive diagnosis of oesophageal varices: Is it useful in compensated cirrhosis?― Digestive and Liver Disease, 2012, 44, 965.	0.9	0
207	Efficacy, safety, tolerability, and PK of the HDAC inhibitor resminostat in sorafenib-refractory hepatocellular carcinoma (HCC): Phase II SHELTER study Journal of Clinical Oncology, 2012, 30, 4115-4115.	1.6	4
208	Reassessment of the role of methane production between irritable bowel syndrome and functional constipation. Journal of Gastrointestinal and Liver Diseases, 2012, 21, 157-63.	0.9	28
209	Full-Dose Peginterferon Alfa-2a and Low-Dose Ribavirin Treatment of Genotypes 1 and 4 Chronic Hepatitis CPatients With End-Stage Renal Disease. Clinical Gastroenterology and Hepatology, 2011, 9, 1004.	4.4	2
210	Barcelona Clinic Liver Cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre, cohort study. Lancet Oncology, The, 2011, 12, 654-662.	10.7	135
211	IL28B rs12979860 C/T polymorphism in elderly chronic hepatitis C patients treated with pegylatedâ€interferon and ribavirin. Alimentary Pharmacology and Therapeutics, 2011, 34, 398-400.	3.7	2
212	Epidemiology of thrombocytopenia in patients with chronic hepatitis C: more than meets the eye. Journal of Viral Hepatitis, 2011, 18, 8-10.	2.0	9
213	Relative decrease in the role played by hepatitis B virus infection in the aetiology of hepatocellular carcinoma during a 20-year period: a multicentre Italian study. Liver International, 2011, 31, 192-196.	3.9	8
214	Alpha-fetoprotein in hepatocellular carcinoma surveillance: Wake not the dead. Hepatology, 2011, 54, 376-377.	7.3	10
215	Use of the platelet count/spleen diameter ratio for the noninvasive diagnosis of esophageal varices in patients with schistosomiasis. Saudi Journal of Gastroenterology, 2011, 17, 307.	1.1	19
216	Small Intestinal Bacterial Overgrowth and Helicobacter pylori : Can They Be Cause of Thrombocytopenia in Patients With Chronic Liver Disease?. American Journal of Gastroenterology, 2011, 106, 1171-1172.	0.4	3

#	Article	IF	CITATIONS
217	Final Results of Open-Label Treatment with Eltrombopag During ENABLE 1: A Study of Eltrombopag As An Adjunct for Antiviral Treatment of Hepatitis C Virus Associated with Thrombocytopenia. Blood, 2011, 118, 2232-2232.	1.4	4
218	Successful antiviral therapy determines a significant decrease in squamous cell carcinoma antigenâ€associated (SCCA) variants' serum levels in antiâ€HCV positive cirrhotic patients*. Journal of Viral Hepatitis, 2010, 17, 563-568.	2.0	16
219	Predictive Factors for Response to Peginterferon-Alpha and Ribavirin Treatment of Chronic HCV Infection in Patients Aged 65 Years and More. Digestive Diseases and Sciences, 2010, 55, 3193-3199.	2.3	14
220	Transarterial chemoembolization in Child-Pugh class B patients with hepatocellular carcinoma: between the devil and the deep blue sea. Liver International, 2010, 30, 923-924.	3.9	5
221	Impact of evidenceâ€based medicine on the treatment of patients with unresectable hepatocellular carcinoma. Alimentary Pharmacology and Therapeutics, 2010, 31, 493-501.	3.7	30
222	Sustained virological response to pegylated interferon and ribavirin is maintained during longâ€ŧerm followâ€up of chronic hepatitis C patients. Alimentary Pharmacology and Therapeutics, 2010, 31, 502-508.	3.7	44
223	Clinical trial: the combination of rifaximin with partially hydrolysed guar gum is more effective than rifaximin alone in eradicating small intestinal bacterial overgrowth. Alimentary Pharmacology and Therapeutics, 2010, 32, 1000-1006.	3.7	62
224	Treatments for hepatocellular carcinoma in elderly patients are as effective as in younger patients: a 20-year multicentre experience. Gut, 2010, 59, 387-396.	12.1	145
225	"Blessed Are Those Who Have Not Seen and Yet Have Believed― American Journal of Gastroenterology, 2010, 105, 227-228.	0.4	0
226	Incidence of Bleeding Following Invasive Procedures in Patients With Thrombocytopenia and Advanced Liver Disease. Clinical Gastroenterology and Hepatology, 2010, 8, 899-902.	4.4	161
227	Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. Journal of Hepatology, 2010, 53, 291-297.	3.7	281
228	Patent Paraumbilical Vein-Induced Hepatic Encephalopathy. Clinical Gastroenterology and Hepatology, 2010, 8, A28.	4.4	1
229	Further insights into the causes of thrombocytopenia in chronic hepatitis C. Journal of Gastrointestinal and Liver Diseases, 2010, 19, 357-8.	0.9	3
230	A Review on the Use of Eltrombopag in Patients with Advanced Liver Disease. Clinical Medicine Therapeutics, 2009, 1, CMT.S2267.	0.1	0
231	Pro: Cirrhotic Patients With Small Esophageal Varices Should Undergo Primary Prophylaxis. American Journal of Gastroenterology, 2009, 104, 2132-2134.	0.4	2
232	Early and very early hepatocellular carcinoma: when and how much do staging and choice of treatment really matter? A multi-center study. BMC Cancer, 2009, 9, 33.	2.6	79
233	Elevations in alanine aminotransferase levels late in the course of antiviral therapy in hepatitis C virus RNA-negative patients are associated with virological relapse. Hepatology, 2009, 49, 1442-1448.	7.3	17
234	Clinical and virological survey of patients with hepatitis B surface antigen in an Italian region: Clinical considerations and disease burden. Journal of Medical Virology, 2009, 81, 1882-1886.	5.0	15

#	Article	IF	CITATIONS
235	External Validation of the Platelet Count/Spleen Diameter Ratio for the Diagnosis of Esophageal Varices in Hepatitis C Virus-Related Cirrhosis. Digestive Diseases and Sciences, 2009, 54, 654-660.	2.3	55
236	Predictive value of onâ€treatment response during fullâ€dose antiviral therapy of patients with hepatitis C virus cirrhosis and portal hypertension. Journal of Internal Medicine, 2009, 266, 537-546.	6.0	25
237	HCV and fat: Something is missing. Journal of Hepatology, 2009, 50, 421-422.	3.7	1
238	Semiannual versus annual surveillance of cirrhotic patients for early diagnosis of hepatocellular carcinoma: Is there a winner?. Digestive and Liver Disease, 2009, 41, A5-A6.	0.9	0
239	Hepatocellular Carcinoma in Patients With Cryptogenic Cirrhosis. Clinical Gastroenterology and Hepatology, 2009, 7, 580-585.	4.4	48
240	A Significant Proportion of Patients With Chronic Hepatitis B Who are Candidates for Antiviral Treatment are Untreated. Journal of Clinical Gastroenterology, 2009, 43, 1001-1007.	2.2	22
241	Positive Glucose Breath Testing is More Prevalent in Patients With IBS-like Symptoms Compared With Controls of Similar Age and Gender Distribution. Journal of Clinical Gastroenterology, 2009, 43, 962-966.	2.2	59
242	Is female sex a significant favorable prognostic factor in hepatocellular carcinoma?. European Journal of Gastroenterology and Hepatology, 2009, 21, 1212-1218.	1.6	51
243	275 PREDICTIVE VALUE OF RAPID VIROLOGICAL RESPONSE IN PATIENTS WITH HCV CIRRHOSIS TREATED WITH PEGYLATED INTERFERON AND RIBAVIRIN. Journal of Hepatology, 2008, 48, S110.	3.7	0
244	Management Strategy for Patients With Gastroesophageal Reflux Disease: A Comparison Between Empirical Treatment With Esomeprazole and Endoscopy-Oriented Treatment. American Journal of Gastroenterology, 2008, 103, 267-275.	0.4	60
245	Thrombocytopenia in liver disease. Current Opinion in Hematology, 2008, 15, 473-480.	2.5	81
246	Surveillance for Early Diagnosis of Hepatocellular Carcinoma: Is It Effective in Intermediate/Advanced Cirrhosis?. American Journal of Gastroenterology, 2007, 102, 2448-2457.	0.4	110
247	Impact of Etiology of Cirrhosis on the Survival of Patients Diagnosed With Hepatocellular Carcinoma During Surveillance. CME. American Journal of Gastroenterology, 2007, 102, 1022-1031.	0.4	54
248	Validation of a Multivariate Model Predicting Presence and Size of Varices. Journal of Clinical Gastroenterology, 2007, 41, 609-615.	2.2	58
249	[274] SURVEILLANCE FOR EARLY DIAGNOSIS OF HEPATOCELLULAR CARCINOMA: IS IT EFFECTIVE IN INTERMEDIATE/ADVANCED CIRRHOSIS?. Journal of Hepatology, 2007, 46, S110.	3.7	1
250	Early and very early HCC. Digestive and Liver Disease, 2007, 39, A36-A37.	0.9	1
251	Predictors of pathological severity in non-alcoholic fatty liver disease: Is East meeting West in the middle?. Journal of Gastroenterology and Hepatology (Australia), 2007, 22, 461-463.	2.8	1
252	Prevalence and Prognostic Significance of the Presence of Esophageal Varices in Patients With Hepatocellular Carcinoma. Clinical Gastroenterology and Hepatology, 2006, 4, 1378-1384.	4.4	69

#	Article	IF	CITATIONS
253	Can Helicobacter pylori Eradication Regimens be Shortened in Clinical Practice? An Open-label, Randomized, Pilot Study of 4 and 7-day Triple Therapy With Rabeprazole, High-dose Levofloxacin, and Tinidazole. Journal of Clinical Gastroenterology, 2006, 40, 515-520.	2.2	16
254	A Simple Approach to Noninvasively Identifying Significant Fibrosis in Chronic Hepatitis C Patients in Clinical Practice. Journal of Clinical Gastroenterology, 2006, 40, 521-527.	2.2	28
255	Hyaluronic acid and aspartate aminotransferase levels normalized by liver function can reflect sinusoidal impairment in chronic liver disease. Liver International, 2006, 26, 439-444.	3.9	2
256	Noninvasive ratio indexes to evaluate fibrosis staging in chronic hepatitis C: role of platelet count/spleen diameter ratio index Journal of Internal Medicine, 2006, 260, 142-150.	6.0	40
257	A study of 4- and 7-day triple therapy with rabeprazole, high-dose levofloxacin and tinidazole rescue treatment for Helicobacter pylori eradication. Alimentary Pharmacology and Therapeutics, 2006, 23, 281-287.	3.7	22
258	Review article: thrombocytopenia in chronic liver disease and pharmacologic treatment options. Alimentary Pharmacology and Therapeutics, 2006, 23, 1055-1065.	3.7	166
259	Monitoring Cytochrome P-450 Activity During Rabeprazole Treatment in Patients with Gastresophageal Reflux Disease. Digestive Diseases and Sciences, 2006, 51, 1602-1606.	2.3	8
260	A Comparison Between Sodium Alginate and Magaldrate Anhydrous in the Treatment of Patients with Gastroesophageal Reflux Symptoms. Digestive Diseases and Sciences, 2006, 51, 1904-1909.	2.3	31
261	Role of partially hydrolyzed guar gum in the treatment of irritable bowel syndrome. Nutrition, 2006, 22, 334-342.	2.4	96
262	Eligibility Criteria for Antiviral Therapy in HCV-Positive Patients: Similar Things to (Almost) Similar People. American Journal of Gastroenterology, 2006, 101, 406-407.	0.4	6
263	Platelet Count/Spleen Diameter Ratio for the Noninvasive Diagnosis of Esophageal Varices: Results of a Multicenter, Prospective, Validation Study. American Journal of Gastroenterology, 2006, 101, 2511-2519.	0.4	215
264	Hyaluronic acid and aspartate aminotransferase levels normalized by liver function can reflect sinusoidal impairment in chronic liver disease. Liver International, 2006, .	3.9	0
265	Longitudinal Modifications of the MELD Score Have Prognostic Meaning in Patients With Liver Cirrhosis. Journal of Clinical Gastroenterology, 2005, 39, 912-914.	2.2	11
266	Influence of 1-Week Helicobacter pylori Eradication Therapy with Rabeprazole, Clarithromycin, and Metronidazole on 13C-Aminopyrine Breath Test. Digestive Diseases and Sciences, 2005, 50, 1207-1213.	2.3	15
267	C-galactose breath test and C-aminopyrine breath test for the study of liver function in chronic liver disease. Clinical Gastroenterology and Hepatology, 2005, 3, 279-285.	4.4	41
268	Liver enzyme alteration: a guide for clinicians. Cmaj, 2005, 172, 367-379.	2.0	1,300
269	5-ASA and colorectal cancer chemoprevention in inflammatory bowel disease: Can we afford to wait for †best evidence'?. Digestive and Liver Disease, 2005, 37, 723-731.	0.9	22
270	Application of the platelet count/spleen diameter ratio to rule out the presence of oesophageal varices in patients with cirrhosis: A validation study based on follow-up. Digestive and Liver Disease, 2005, 37, 779-785.	0.9	75

#	Article	IF	CITATIONS
271	Non-invasive assessment of liver function: trying not to miss an opportunity. Alimentary Pharmacology and Therapeutics, 2004, 19, 827-828.	3.7	1
272	Reply to Farina ti et al.: classification of 'intermediate stage', untreated hepatocellular carcinoma patients: the neighbour's grass is not so green. Journal of Internal Medicine, 2004, 256, 531-531.	6.0	0
273	A reappraisal of the Barcelona Clinic Liver Cancer model: natural history of untreated 'intermediate stage' hepatocellular carcinoma. Journal of Internal Medicine, 2004, 256, 529-530.	6.0	1
274	Can inclusion of serum creatinine values improve the Child-Turcotte-Pugh score and challenge the prognostic yield of the model for end-stage liver disease score in the short-term prognostic assessment of cirrhotic patients?*. Liver International, 2004, 24, 465-470.	3.9	30
275	High Ascitic Fluid Leptin Levels in Patients with Decompensated Liver Cirrhosis and Sterile Ascites: Relationship with TNF-Â Levels. Digestive Diseases and Sciences, 2004, 49, 275-280.	2.3	7
276	Prognosis of hepatocellular carcinoma in anti-HCV positive cirrhotic patients: a single-centre comparison amongst four different staging systems. Journal of Internal Medicine, 2004, 255, 399-408.	6.0	24
277	Combined multichannel intraluminal impedance and pH-metry: a novel technique to improve detection of gastro-oesophageal reflux. Digestive and Liver Disease, 2004, 36, 565-569.	0.9	75
278	13C-breath tests and liver fibrosis. European Review for Medical and Pharmacological Sciences, 2004, 8, 51-4.	0.7	15
279	Noninvasive diagnosis of fibrosis: The truth is rarely pure and never simple. Hepatology, 2003, 38, 1312-1313.	7.3	33
280	Helicobacter pylori infection is associated with greater impairment of cytochrome P-450 liver metabolic activity in anti-HCV positive cirrhotic patients. Digestive Diseases and Sciences, 2003, 48, 802-808.	2.3	18
281	Previous hepatitis B virus infection is associated with worse disease stage and occult hepatitis B virus infection has low prevalence and pathogenicity in hepatitis C virusâ€positive patients. Liver International, 2003, 23, 12-18.	3.9	45
282	Trans-catheter arterial chemoembolisation for hepatocellular carcinoma in patients with viral cirrhosis: role of combined staging systems, Cancer Liver Italian Program (CLIP) and Model for End-stage Liver Disease (MELD), in predicting outcome after treatm. Alimentary Pharmacology and Therapeutics, 2003, 17, 1563-1569.	3.7	45
283	Utility of the MELD score for assessing 3-month survival in patients with liver cirrhosis: one more positive answer. Gastroenterology, 2003, 125, 993-994.	1.3	22
284	Utility of the MELD score for assessing 3-month survival in patients with liver cirrhosis: one more positive answer. Gastroenterology, 2003, 125, 992-993.	1.3	26
285	MELD scoring system is useful for predicting prognosis in patients with liver cirrhosis and is correlated with residual liver function: a European study. Gut, 2003, 52, 134-139.	12.1	269
286	The Metabolic Syndrome: All Criteria Are Equal, but Some Criteria Are More Equal Than Others—Reply. Archives of Internal Medicine, 2003, 163, 2788.	3.8	16
287	Platelet count/spleen diameter ratio: proposal and validation of a non-invasive parameter to predict the presence of oesophageal varices in patients with liver cirrhosis. Gut, 2003, 52, 1200-1205.	12.1	380
288	Validity and Clinical Utility of the Aspartate Aminotransferase–Alanine Aminotransferase Ratio in Assessing Disease Severity and Prognosis in Patients With Hepatitis C Virus–Related Chronic Liver Disease. Archives of Internal Medicine, 2003, 163, 218.	3.8	295

#	Article	IF	CITATIONS
289	Relationship between thrombopoietin serum levels and liver function in patients with chronic liver disease related to hepatitis C virus infection. American Journal of Gastroenterology, 2003, 98, 2516-2520.	0.4	79
290	Relationship between thrombopoietin serum levels and liver function in patients with chronic liver disease related to hepatitis C virus infection. American Journal of Gastroenterology, 2003, 98, 2516-2520.	0.4	1
291	Surveillance for hepatocellular carcinoma in liver cirrhosis: have programmes improved because patients have?. Gut, 2002, 51, 456-a-457.	12.1	1
292	Intravenous immunoglobulin for recurrent Clostridium difficile diarrhoea. Gut, 2002, 51, 456-456.	12.1	56
293	Influence of age on clinical presentation, therapeutic options, and prognosis in anti-HCV positive cirrhotic patients with hepatocellular carcinoma. Age and Ageing, 2002, 31, 457-462.	1.6	11
294	Surveillance for hepatocellular carcinoma in liver cirrhosis: have programmes improved because patients have?. Gut, 2002, 51, 611-611.	12.1	0
295	The 1-year and 3-month prognostic utility of the AST/ALT ratio and model for end-stage liver disease score in patients with viral liver cirrhosis. American Journal of Gastroenterology, 2002, 97, 2855-2860.	0.4	59
296	Serum thrombopoietin levels are linked to liver function in untreated patients with hepatitis C virus-related chronic hepatitis. Journal of Hepatology, 2002, 37, 572-577.	3.7	97
297	Relationships between MELD scoring system, Child-Pugh's score, and residual liver function in a European series of cirrhotic patients. Journal of Hepatology, 2002, 36, 47.	3.7	0
298	AST/ALT ratio has prognostic value in the assessment of 1-year survival of patients with viral cirrhosis: comparison with MELD and Child-Pugh's scores. Journal of Hepatology, 2002, 36, 52-53.	3.7	1
299	13 C-Aminopyrine breath test to evaluate severity of disease in patients with chronic hepatitis C virus infection. Alimentary Pharmacology and Therapeutics, 2002, 16, 717-725.	3.7	48
300	Can Changing Counseling Strategy Change the Picture of the Chronic Hepatitis C Patient Population?. Archives of Internal Medicine, 2002, 162, 2497-2498.	3.8	0
301	Monitoring of liver metabolic function during interferon-alpha therapy and its relationship to treatment outcome in chronic hepatitis C patients. Hepato-Gastroenterology, 2002, 49, 778-82.	0.5	0
302	The 1-year and 3-month prognostic utility of the AST/ALT ratio and model for end-stage liver disease score in patients with viral liver cirrhosis. American Journal of Gastroenterology, 2002, 97, 2855-2860.	0.4	0
303	Persistently normal aminotransferase in chronic hepatitis C virus infection: is it time to redefine parameters of "normality�. Digestive and Liver Disease, 2001, 33, 202-203.	0.9	0
304	Leptin in nonalcoholic steatohepatitis: is it one of the "hits�. American Journal of Gastroenterology, 2001, 96, 2519-2520.	0.4	6
305	Steatosis in chronic hepatitis C: can weight reduction improve therapeutic efficacy?. Journal of Hepatology, 2001, 35, 432-433.	3.7	31
306	Serum (LPTS) and ascitic leptin (LPTA) levels in decompensated cirrhotic patients. Journal of Hepatology, 2001, 34, 202.	3.7	5

#	Article	IF	CITATIONS
307	Platelets/spleen area ratio reflects progressive liver disease. Journal of Hepatology, 2001, 34, 235.	3.7	0
308	Liver iron accumulation in chronic hepatitis C patients without HFE mutations: relationships with histological damage, viral load and genotype and α-glutathione S-transferase levels. European Journal of Gastroenterology and Hepatology, 2001, 13, 1355-1361.	1.6	26
309	Serum pro-collagen III peptide levels are related to lobular necrosis in untreated patients with chronic hepatitis C. European Journal of Gastroenterology and Hepatology, 2001, 13, 137-141.	1.6	15
310	Impairment of cytochrome P-450-dependent liver activity in cirrhotic patients with Helicobacter pylori infection. Alimentary Pharmacology and Therapeutics, 2001, 15, 1967-1973.	3.7	11
311	Long-term follow up of chronic hepatitis C patients after alpha-interferon treatment: A functional study. Journal of Gastroenterology and Hepatology (Australia), 2001, 16, 399-405.	2.8	10
312	Increased levels of gammaGT suggest the presence of bile duct lesions in patients with chronic hepatitis C: absence of influence of HCV genotype, HCV-RNA serum levels, and HGV infection on this histological damage. Digestive Diseases and Sciences, 2001, 46, 524-529.	2.3	32
313	Chronic hepatitis C in different populations: Similar patterns of alanine aminotransferase alteration characterize similar clinical subgroups. Hepatology, 2001, 33, 313-313.	7.3	1
314	Leptin in nonalcoholic steatohepatitis: is it one of the "hits�. American Journal of Gastroenterology, 2001, 96, 2519-2520.	0.4	3
315	Transportability and reproducibility of the AST/ALT ratio in chronic hepatitis C patients. American Journal of Gastroenterology, 2001, 96, 918-919.	0.4	21
316	Transportability and reproducibility of the AST/ALT ratio in chronic hepatitis C patients. American Journal of Gastroenterology, 2001, 96, 918-919.	0.4	5
317	Utility of α-Glutathione S-transferase assessment in chronic hepatitis C patients with near normal alanine aminotransferase levels. Clinical Biochemistry, 2000, 33, 297-301.	1.9	17
318	Oral or intravenous lidocaine administration to perform megx test?. Digestive Diseases and Sciences, 2000, 45, 1011-1012.	2.3	0
319	Is Aspartate Aminotransferase Enough?. American Journal of Gastroenterology, 2000, 95, 3687-3688.	0.4	1
320	Leptin has no role in determining severity of steatosis and fibrosis in patients with chronic hepatitis C. American Journal of Gastroenterology, 2000, 95, 3211-3217.	0.4	52
321	Influence of Helicobacter Pylori Eradication Therapy on 13C Aminopyrine Breath Test: Comparison Among Omeprazole-, Lansoprazole-, Or Pantoprazole-Containing Regimens. American Journal of Gastroenterology, 2000, 95, 2762-2767.	0.4	14
322	Is there a role for multiple quantitative liver function tests?. Digestive and Liver Disease, 2000, 32, 644.	0.9	2
323	Influence of two-weeks Helicobacter Pylori eradication therapy on 13C aminopyrine breath test. Gastroenterology, 2000, 118, A1238.	1.3	0
324	Serum leptin levels in patients with viral chronic hepatitis or liver cirrhosis. Journal of Hepatology, 2000, 33, 33-37.	3.7	116

#	Article	IF	CITATIONS
325	Cholestasis seems to be the major determinant of altered CA 19-9 levels in patients with liver cirrhosis, with and without hepatocellular carcinoma. Journal of Hepatology, 2000, 32, 155.	3.7	0
326	Bile duct lesions in chronic hepatitis C: Biochemical and virological relationships with histological damage. Journal of Hepatology, 2000, 32, 179.	3.7	0
327	Echo-doppler hepatic measurements combined with quantitative liver function tests in chronic liver disease. Journal of Hepatology, 2000, 32, 223.	3.7	0
328	The Monoethylglycinexylidide Test Does Not Impair Psychometric Performance in Patients With Chronic Hepatitis or Cirrhosis. Therapeutic Drug Monitoring, 2000, 22, 371-374.	2.0	2
329	Histologic Determinants of Monoethylglycinexylidide Formation in Patients With Chronic Hepatitis C. Therapeutic Drug Monitoring, 2000, 22, 455-459.	2.0	3
330	Influence of Helicobacter pylori eradication therapy on 13C aminopyrine breath test: comparison among omeprazole-, lansoprazole-, or pantoprazole-containing regimens. American Journal of Gastroenterology, 2000, 95, 2762-2767.	0.4	0
331	Leptin has no role in determining severity of steatosis and fibrosis in patients with chronic hepatitis C. American Journal of Gastroenterology, 2000, 95, 3211-3217.	0.4	0
332	Steatosis and bile duct damage in chronic hepatitis C: distribution and relationships in a group of Northern Italian patients. Liver International, 1999, 19, 432-437.	3.9	50
333	Progressive liver functional impairment is associated with an increase in AST/ALT ratio. Digestive Diseases and Sciences, 1999, 44, 1249-1253.	2.3	192
334	Can the MEGX test and serum bile acids improve the prognostic ability of Child-Pugh's score in liver cirrhosis?. European Journal of Gastroenterology and Hepatology, 1999, 11, 559-564.	1.6	35
335	Chronic liver disease related to hepatitis C virus. European Journal of Gastroenterology and Hepatology, 1999, 11, 553-558.	1.6	9
336	Need for independence of treatment allocation from prognostic evaluation for hepatocellular carcinoma. Liver Cancer International, 0, , .	1.3	2